Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 37-41

  Moran, Sarah ^a   Little, Mark A ^b  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

antineutrophil cytoplasmic antibody; kidney transplant; relapse; vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANCA ASSOCIATED VASCULITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMODIALYSIS PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; POLYARTERITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL; WEGENER GRANULOMATOSIS; WHOLE BODY RADIATION;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROGNOSIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890155527     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000006     Document Type: Review

References (39)

1. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 2003; 41:776-784.
2. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998; 9:1258-1263.
3. Cohen BA, Clark WF. Pauci-immune renal vasculitis: Natural history, prognostic factors, and impact of therapy. Am J Kidney Dis 2000; 36:914-924.
4. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: Effect of functional status and nonvasculitic co-morbidity. Nephrol Dial Transplant 2004; 19:356-364.
5. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9:842-852.
6. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69:1036-1043.
7. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
8. Weidemann S, Andrassy K, Ritz E. ANCA in haemodialysis patients. Nephrol Dial Transplant 1993; 8:839-845.
9. European renal association - European dialysis and transplant association. http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2011.pdf
10. Watts RA, Gonzalez-Gay MA, Lane SE, et al. Geoepidemiology of systemic vasculitis: Comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60:170-172.
11. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis Rheum 2000; 43:414-419.
12. Watts RA, Scott DG, Lane SE. Epidemiology of Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. Cleve Clin J Med 2002; 69 (Suppl 2):SII84-SII86.
13. Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 2008; 38:816-823.
14. Segelmark M. L23. Renal transplantation in ANCA-associated vasculitis. Presse Med 2013; 42:568-571.
15. De Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013; 8:1709-1717.
16. Schmitt WH, Haubitz M, Mistry N, et al. Renal transplantation in Wegener's granulomatosis. Lancet 1993; 342:860.
17. Göçeroǧ lu A, Rahmattulla C, Berden A, et al. Dutch Transplantation in Vasculitis (DUTRAVAS)-study: Update on the outcome of renal transplantation in ANCA-associated vasculitis (AAV) patients in the Netherlands. La Presse Méd 2013; 42:658-659.
18. Marco H, Mirapeix E, Arcos E, et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 2013; 27:338-347.
19. Geetha D, Eirin A, True K, et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation 2011; 91:1370-1375.
20. Little MA, Hassan B, Jacques S, et al. Renal transplantation in systemic vasculitis: When is it safe? Nephrol Dial Transplant 2009; 24:3219-3225.
21. Gera M, Griffin MD, Specks U, et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression. Kidney Int 2007; 71:1296-1301.
22. Moroni G, Torri A, Gallelli B, et al. The long-term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007; 7:2133-2139.
23. Deegens JK, Artz MA, Hoitsma AJ, Wetzels JF. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease. Clin Nephrol 2003; 59:1-9.
24. Elmedhem A, Adu D, Savage CO. Relapse rate and outcome of ANCAassociated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003; 18:1001-1004.
25. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103-109.
26. Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999; 56:1544-1550.
27. Reaich D, Cooper N, Main J. Rapid catastrophic onset of Wegener's granulomatosis in a renal transplant. Nephron 1994; 67:354-357.
28. Lowance DC, Vosatka K, Whelchel J, et al. Recurrent Wegener's granulomatosis. Am J Med 1992; 92:573-575.
29. Steinman TI, Jaffe BF, Monaco AP, et al. Recurrence of Wegener's granulomatosis after kidney transplantation: Successful re-induction of remission with cyclophosphamide. Am J Med 1980; 68:458-460.
30. Haubitz M, Olbricht CJ, Maschek H, et al. Lethal relapse of Wegener's disease 4 years after successful kidney transplantation. Nephron 1995; 71:118- 120.
31. Rosenstein ED, Ribot S, Ventresca E, Kramer N. Recurrence of Wegener's granulomatosis following renal transplantation. Br J Rheumatol 1994; 33: 869-871.
32. Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181-1184.
33. Schmitt WH, van der Woude FJ. Organ transplantation in the vasculitides. Curr Opin Rheumatol 2003; 15:22-28.
34. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006; 45:724-729.
35. Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12:394-402.
36. Netzer KO, Merkel F, Weber M. Goodpasture syndrome and end-stage renal failure: To transplant or not to transplant? Nephrol Dial Transplant 1998; 13:1346-1348.
37. Kluth DC, Rees AJ. Antiglomerular basement membrane disease. J Am Soc Nephrol 1999; 10:2446-2453.
38. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994; 87:671-678.
39. Beck L, Bomback AS, Choi MJ, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis. Am J Kidney Dis 2013; 62:403-441.